Long-term Monitoring of Growth and Development of Pediatric Patients Previously Treated With Everolimus (EXIST-LT)
Long-term Follow-up Study to Monitor the Growth and Development of Pediatric Patients Previously Treated With Everolimus in Study CRAD001M2301 (EXIST-LT)
Sponsor: Novartis Pharmaceuticals
A PHASE4 clinical study on Growth and Development, this trial is completed. The trial is conducted by Novartis Pharmaceuticals and has accumulated 17 data snapshots since 2014. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
17 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE4
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE4
-
Mar 2024 — Jul 2024 [monthly]
Completed PHASE4
-
Feb 2024 — Mar 2024 [monthly]
Completed PHASE4
Status: Active Not Recruiting → Completed
▶ Show 12 earlier versions
-
Aug 2023 — Feb 2024 [monthly]
Active Not Recruiting PHASE4
-
Jan 2023 — Aug 2023 [monthly]
Active Not Recruiting PHASE4
-
Jan 2022 — Jan 2023 [monthly]
Active Not Recruiting PHASE4
-
Sep 2021 — Jan 2022 [monthly]
Active Not Recruiting PHASE4
-
Feb 2021 — Sep 2021 [monthly]
Active Not Recruiting PHASE4
-
Jan 2021 — Feb 2021 [monthly]
Active Not Recruiting PHASE4
-
Mar 2020 — Jan 2021 [monthly]
Active Not Recruiting PHASE4
-
Dec 2018 — Mar 2020 [monthly]
Active Not Recruiting PHASE4
-
Jun 2018 — Dec 2018 [monthly]
Active Not Recruiting PHASE4
-
Jul 2017 — Jun 2018 [monthly]
Active Not Recruiting PHASE4
-
Feb 2017 — Jul 2017 [monthly]
Active Not Recruiting PHASE4
-
Jan 2017 — Feb 2017 [monthly]
Active Not Recruiting PHASE4
First recorded
Dec 2014
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Novartis Pharmaceuticals
For direct contact, visit the study record on ClinicalTrials.gov .